Membrane active peptides with the ability to cross the plasma membrane represent a promising class of therapeutic compounds. However, translocation efficacy and membrane toxicity of these peptides appear correlated and a better understanding of their mechanisms of action is needed to achieve the desired effect. Here, a range of coarse grain molecular dynamics simulations have been performed to systematically investigate the interactions of such cell-penetrating peptides (CPPs) with biologically relevant membranes. Challenges associated to the development of a suitable asymmetric mammalian membrane model demonstrated the importance of lipid species distribution on the bilayer mechanical properties, as well as the effect of coarse graining on its electrostatic properties. However, simulations successfully discriminated between two CPPs, penetratin and transportan, and were consistent with the experimental data available for these. The results obtained suggest that the ability of transportan peptides to aggregate into flexible, dynamic, transmembrane bundles is responsible for their relative membrane toxicity. The stability and structure of these aggregates, as well as the extent of the bilayer perturbations they induced, were shown to depend on the membrane composition and asymmetry, thus providing a molecular basis to explain how the toxicity of CPPs is modulated by membranes. In particular, bilayer destabilisation was enhanced by the presence of anionic lipids and hampered by that of cholesterol. Transportan aggregates were also observed to trigger lipid flip-flops above a certain size and a new pathway for such events, not relying on the formation of water defects, was characterised.

Les peptides vecteurs (CPP) présentent un grand intérêt pour l'internalisation de principes actifs dans les cellules. Les mécanismes permettant aux peptides de traverser la membrane restent sujets à discussion. Mieux comprendre leurs interactions avec la membrane pourrait permettre d'améliorer leur efficacité. L'organisation des lipides après interaction avec le peptide pénétratine a été étudiée par DSC et par fluorescence du Laurdan, sur des membranes modèles composées de lipides naturels. La pénétratine a induit de l'hétérogénéité dans la membrane, ce qui pourrait être un élément important pour déstabiliser la membrane durant son internalisation dans la cellule. En outre, le cholestérol est un régulateur parmi les plus importants des domaines membranaires. En raison de son affinité pour les lipides saturés, il peut former des domaines ordonnés. Grâce au cholestérol-pyrène, une sonde fluorescente, nous avons étudié les domaines liquides ordonnés (Lo) et désordonnés (Ld) de la membrane. Nous avons, par analyse statistique en composante principale, déterminé les longueurs d'onde d'émission caractéristiques des domaines Lo et Ld. Les peptides pénétratine, R9 et RW9 diminuent l'assemblage du cholestérol et RW9 augmente la fluidité de la membrane. RW9 a été le seul peptide capable de traverser des membranes (Ld) sur de vésicules lipidiques dans nos conditions expérimentales. Nous pouvons ainsi en déduire que la distribution des lipides dans la membrane est un factor important pour le passage des CPP. Notamment, l'interface entre les différents domaines semble jouer un rôle prépondérant pour l'internalisation. / Cell penetrating peptides are promising vectors for molecular drug delivery in eukaryotic cells. Despite of their discovery 20 years ago, the mechanisms of peptide membrane crossing are still controversial. Understanding then how they modify the membrane will allow later on a more efficient internalisation into the cell. Lipid organisation after penetratin interaction was studied by DSC and Laurdan fluorescence. Penetratin was able to induce membrane heterogeneity, which could be important for membrane destabilisation during cell internalisation. Furthermore, cholesterol is one of the most important regulators of membrane domains. Due to its strong affinity with saturated lipids, cholesterol presents the ability to form “rafts” (ordered domains). By cholesterol-pyrene, which is a probe that mimics cholesterol, we studied the liquid ordered (Lo) and liquid disordered (Ld) domains of the membrane. Firstly, we determined the wavelengths that characterise each of these domains by multivariable analysis and then, we verify the peptide effect (R9, RW9 and penetratin) in the distribution of these domains. RW9 were the only CPP able to cross the membrane (Ld). We can deduce that lipid distribution in the membrane is important for the peptide internalisation and the interfaces between these domains may play an important role during this process.

Gene therapy holds the promise of revolutionizing the way we treat diseases. By using recombinant DNA and oligonucleotides (ONs), gene functions can be restored, altered or silenced according to the therapeutic need. However, gene therapy approaches require the delivery of large and charged nucleic acid-based molecules to their intracellular targets across the plasma membrane, which is inherently impermeable to such molecules. In this thesis, two chemically modified cell-penetrating peptides (CPPs) that have superior delivery properties for several nucleic acid-based therapeutics are developed. These CPPs can spontaneously form nanoparticles upon non-covalent complexation with the nucleic acid cargo, and the formed nanoparticles mediate efficient cellular transfection. In paper I, we show that an N-terminally stearic acid-modified version of transportan-10 (PF3) can efficiently transfect different cell types with plasmid DNA and mediates efficient gene delivery in-vivo when administrated intra muscularly (i.m.) or intradermaly (i.d.). In paper II, a new peptide with ornithine modification, PF14, is shown to efficiently deliver splice-switching oligonucleotides (SSOs) in different cell models including mdx mouse myotubes; a cell culture model of Duchenne’s muscular dystrophy (DMD). Additionally, we describe a method for incorporating the PF14-SSO nanoparticles into a solid formulation that is active and stable even when stored at elevated temperatures for several weeks. In paper III, we demonstrate the involvement of class-A scavenger receptor subtypes (SCARA3 & SCARA5) in the uptake of PF14-SSO nanoparticles, which possess negative surface charge, and suggest for the first time that some CPP-based systems function through scavenger receptors. In paper IV, the ability of PF14 to deliver siRNA to different cell lines is shown and their stability in simulated gastric acidic conditions is highlighted. Taken together, these results demonstrate that certain chemical modifications can drastically enhance the activity and stability of CPPs for delivering nucleic acids after spontaneous nanoparticle formation upon non-covalent complexation. Moreover, we show that CPP-based nanoparticles can be formulated into convenient and stable solid formulations that can be suitable for several therapeutic applications. Importantly, the involvement of scavenger receptors in the uptake of such nanoparticles is presented, which could yield novel possibilities to understand and improve the transfection by CPPs and other gene therapy nanoparticles. / At the time of doctoral defence the following paper was unpublished and had a status as follows: Paper nr 4: Submitted

Conjugation of the Human Immunodeficiency Virus Transactivator of Transcription (TAT) to active proteins allows transport into the intracellular environment. This feature can be harnessed to deliver combinations of reprogramming factors (RFs) such as c-Myc, Oct4, Klf4 and Sox2 into somatic cells to derive induced pluripotent stem cells (iPSCs). For this project, TAT-fusion proteins including four TAT-conjugated RFs (TAT-RFs) have been produced and purified. All four TAT-RFs can bind specific DNA sequences. Bioactivity was tested in live cells using a novel assay based on an engineered fibroblast cell line that can be induced to express RFs by doxycycline and subsequently generate iPSCs. To test each TAT-RF, reprogramming was blocked by transient silencing of a single RF by siRNA and rescued by the corresponding TAT-RF. The results of this assay suggested that TAT-Klf4 was bioactive in cells; however, definitive evidence could not be obtained for other RFs.

Conjugation of the Human Immunodeficiency Virus Transactivator of Transcription (TAT) to active proteins allows transport into the intracellular environment. This feature can be harnessed to deliver combinations of reprogramming factors (RFs) such as c-Myc, Oct4, Klf4 and Sox2 into somatic cells to derive induced pluripotent stem cells (iPSCs). For this project, TAT-fusion proteins including four TAT-conjugated RFs (TAT-RFs) have been produced and purified. All four TAT-RFs can bind specific DNA sequences. Bioactivity was tested in live cells using a novel assay based on an engineered fibroblast cell line that can be induced to express RFs by doxycycline and subsequently generate iPSCs. To test each TAT-RF, reprogramming was blocked by transient silencing of a single RF by siRNA and rescued by the corresponding TAT-RF. The results of this assay suggested that TAT-Klf4 was bioactive in cells; however, definitive evidence could not be obtained for other RFs.

Les peptides pénétrants (CPP) se caractérisent par deux propriétés : ils pénètrent dans l'espace intracellulaire et favorisent l'internalisation de cargaisons moléculaires auxquelles ils sont associés. Si les CPP sont très utilisés comme vecteurs en recherche fondamentale, la méconnaissance des mécanismes de pénétration et de leurs distributions intracellulaires limite leur utilisation thérapeutique. Il est admis que les CPP et leurs cargaisons sont internalisés par transport actif (endocytose) et par transport passif (translocation directe). J'ai étudié la translocation directe à l'échelle moléculaire en utilisant des membranes modèles. Les CPP usuels sont internalisés et permettent l'accumulation de cargaisons dans des vésicules unilamellaires. J'ai alors démontré que la translocation directe se déroule via la formation de complexes neutres et hydrophobes CPP-phospholipides.La pénétration intracellulaire des CPP est le plus souvent étudiée par microscopie confocale. J'ai démontré que des fortes concentrations locales de CPP induit une auto-inhibition de leur fluorophore. Cet artefact a conduit à des erreurs d'interprétation dans la littérature quant à la localisation des CPP. Un protocole permettant de révéler la fluorescence éteinte a été proposé et conduit à réévaluer la localisation subcellulaire des CPP ainsi que l'importance relative des mécanismes d'internalisation.Ces résultats ont permis de développer rationnellement de nouveaux vecteurs pénétrants : les oligoarginines acylées par des chaînes grasses dont des insaturations sont de stéréochimie cis. Leur internalisation passive particulièrement importante conduit à la libération de la cargaison dans le cytosol. / Cell penetrating peptides (CPPs) are short cationic sequences capable of shuttling bioactive cargoes into eukaryotic cells. If CPPs are common delivery tools in basic research, their therapeutic use is currently limited because their internalization mechanisms and intracellular distributions remain to be elucidated. In living cells there is evidence for both endocytosis of the CPPs and for “direct translocation”, an energy-independent uptake pathway. I analyzed the direct translocation phenomenon at the molecular level with model membranes. CPPs are internalized into large unilamellar vesicles and trigger the internalization of various cargoes. I then demonstrated that direct translocation occurs through membranes via the formation of a neutral and hydrophobic CPP-anionic phospholipids complex. CPPs internalization is mostly analyzed by confocal microscopy. I demonstrated that fluorescence self-quenching occurs if fluorescently labeled CPPs are locally too concentrated. This severe artifact led to misinterpretation of the subcellular distribution of CPPs. I developed a reliable procedure to avoid this artifact and ranked subcellular regions of living cells depending on their CPP concentration. As a result, I was able to rationalize the subcellular distribution of CPPs and to deduce their penetration mechanisms. The studies that I performed provided valuable information that I used to design a new family of delivery vectors: minimalist oligoarginines peptides acylated by unsaturated fatty acids (cis unsaturations). The direct translocation of these lipopeptides is particularly important yielding to an efficient delivery of a cargo inside the cytosol of living cells.

Oligonucleotide-based drugs hold great promise for the treatment of many types of diseases, ranging from genetic disorders to viral infections and cancer. The problem is that efficient delivery across the cell membrane is required for oligonucleotides to have their desired effect. Cell-penetrating peptides (CPPs) provide a solution to this problem. CPPs are capable of transporting cargoes such as drugs or nucleic acids for gene therapy into the cell, either by covalent conjugation to the cargo or by non-covalent complex formation. This thesis is focused on the development of a class of peptides called PepFects, peptides with fatty acid modifications capable of forming nanoparticle-sized complexes with oligonucleotides. These complexes are efficiently internalized by many different cell types and are generally non-toxic and non-immunogenic. We have developed a number of novel PepFect peptides and a quantitative structure-activity model to predict the biological effect of our peptides. In addition, the involvement of scavenger receptors class A in the endocytic uptake of PepFect complexes as well as other CPPs and polymeric transfection agents was studied. Lastly, we have developed a series of PepFect peptides for delivery across the blood-brain barrier and a model system mimicking the blood-brain barrier in order to evaluate the passage of these peptides. The general aim of this thesis is to improve the understanding of intracellular delivery of oligonucleotides with PepFect peptides from both a chemical and a biological viewpoint, and further improve the efficacy of this delivery system with the long-term goal of making it useful in clinical settings.

Therapeutically restricted sites present a formidable barrier in medicine. Herein, chemical strategies to overcome two restricted sites, HIV reservoirs and intracellular bacteria, will be discussed. First, cellular and anatomical HIV reservoirs, such as those in the brain, limit HIV eradication using currently known therapeutic regimes. HIV therapies are unable to localize in the brain, in part, due to high expression of efflux transporters, such as P-glycoprotein (P-gp), at the BBB, because many of these therapies are P-gp substrates. In an effort to overcome therapeutically restricted HIV sanctuaries, a dimerized combination HIV therapy was designed to act two-fold. First, the dimeracts as a P-gp inhibitor allowing therapeutic access to restricted sites. Second, the dimeractsas a prodrug, which once in the reducing environment of the cell, may release monomeric HIV therapies. The dual conjugate, Abacavir-S2-Darunavir, was shown to potently inhibit P-gp across two separate cell lines, was able to regenerate the component monomers in a reducing environment and contained modest anti-HIV activity.<div><br><div>Further, mammalian cells create sanctuary sites for bacteria to grow and proliferate, because many common antibiotic therapies are unable to cross the mammalian cell membrane. Therefore, these pathogens are able to proliferate without therapeutic constraint. Here, a chemical strategy was developed to deliver a dual antibiotic therapy inside mammalian cells in an effort to clear these intracellular pathogens. First, a new synthetic strategy was developed for facile synthesis of dual conjugates, composedof an aminoglycoside and a cell penetrating peptide (CPP) linked with a reversible disulfide tether, using kanamycin and the known CPP Arg8as a model system. Next, this synthetic methodology was expanded for use with theaminoglycoside tobramycin and theknown broad-spectrum antibiotic and cell penetrating peptide, P14LRR, once again linked via the reversible disulfide tether (TobP14). Two distinct isomers of TobP14 were synthesized, isolated, and fully characterized by 2D NMR. The TobP14 isomers were shown to be an effective antibiotic across various Gram positive and negative pathogens such as MRSA, S. epidermidis, P. aeruginosa, and A. baumannii. Further, the isomers effectively releasedthe monomeric therapies (tobramycin and P14-SH) in a reducing environment and werenontoxic to mammalian cells up to 16 μM. Finally, the dual conjugate isomers significantly reduce two different strains of intracellular A. baumanniiwithin macrophages.<br><div><br></div><div><br></div></div></div>

De nos jours, une des stratégies majeures dans la modulation de la pharmacocinétique des composés bioactifs est leur vectorisation et l’obtention de formes prodrogues. Ce travail est centré sur la vectorisation d’antitumoraux phosphorés à l’aide de peptides favorisant le passage membranaire. Nous avons alors réalisé la conjugaison d’aminoalkyl-bisphosphonates avec des séquences peptidiques afin de modifier leur temps de rétention dans l’organisme et d’augmenter leur internalisation cellulaire. Différents espaceurs possédant un motif carbonylé insaturé ont été évalués dans le couplage par la réaction d’addition aza- et thiaMichael afin d’aboutir à l’obtention d’un conjugué peptide-alendronate. Une approche prodrogue a également été réalisée avec la synthèse de dérivés de type bisphosphinates et l’obtention d’un analogue de l’alendronate. / Nowadays, one of the main strategies for pharmacokinetic modifications of bioactive compounds is their vectorization and the synthesis of prodrug derivatives. This work is focused on the vectorization of phosphorus antitumor agents with cell-penetrating peptides. We have then conjugated aminoalkyl-bisphosphonates with peptidic sequence to modify their retention time and increase their cellular internalization. Several linkers bearing an insaturated carbonyl moiety have been evaluated in conjugation by aza- and thia-Michael addition reaction to obtain a conjugated peptide-alendronate compounds. A prodrug approach has been conducted with the synthesis of bisphosphinate derivatives and an analog of alendronate has been obtained.

No description available.